Wie hoch ist der Preis für Sienna Biopharmaceuticals, Inc. (SNNAQ)

Preis für Sienna Biopharmaceuticals, Inc. (SNNAQ) ist $0.0001

Wie hoch ist die Marktkapitalisierung für Sienna Biopharmaceuticals, Inc. (SNNAQ)

Marktkapitalisierung für Sienna Biopharmaceuticals, Inc. (SNNAQ) ist $3.09K

Sienna Biopharmaceuticals, Inc. (SNNAQ) Ausstehende Aktien

Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm dedicated to discovering and advancing pharmaceutical treatments across diverse therapeutic fields. Its primary focus involved crafting therapies within immunology and inflammation, specifically targeting particular tissue pathways, notably in the skin. Among its pipeline, SNA-120 stood out as a pioneering, first-in-class inhibitor of tropomyosin receptor kinase A, undergoing Phase IIb clinical evaluation for addressing psoriasis and its associated itching. Another key candidate, SNA-125, a topical dual Janus kinase 3 inhibitor, progressed through Phase I/II clinical studies for conditions like atopic dermatitis, psoriasis, and pruritus. Furthermore, Sienna was advancing SNA-001, a topical suspension incorporating silver particles, into pivotal clinical trials not only for acne treatment but also for diminishing light-colored hair, encompassing shades such as white, gray, blonde, light brown, and light red. Established in 2010 and based in Westlake Village, California, the company originally operated as Sienna Labs, Inc. before rebranding as Sienna Biopharmaceuticals, Inc. in February 2016. However, the firm faced significant financial challenges, initiating Chapter 11 bankruptcy proceedings on September 16, 2019, which subsequently converted to Chapter 7 liquidation on December 18, 2019.

Jahr	Ausstehende Aktien	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Ausstehende Aktien

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Ausstehende Aktien	Unterschied	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	0.00	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Unternehmen

Ausstehende Aktien

Unterschied

Land